Literature DB >> 28564602

Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.

Daniel Henry Marks1, Rozario Thomas2, Yvette Chin2, Riddhi Shah2, Christine Khoo2, Robert Benezra3.   

Abstract

The mitotic checkpoint ensures proper segregation of chromosomes by delaying anaphase until all kinetochores are bound to microtubules. This inhibitory signal is composed of a complex containing Mad2, which inhibits anaphase progression. The complex can be disassembled by p31comet and TRIP13; however, TRIP13 knockdown has been shown to cause only a mild mitotic delay. Overexpression of checkpoint genes, as well as TRIP13, is correlated with chromosomal instability (CIN) in cancer, but the initial effects of Mad2 overexpression are prolonged mitosis and decreased proliferation. Here, we show that TRIP13 overexpression significantly reduced, and TRIP13 reduction significantly exacerbated, the mitotic delay associated with Mad2 overexpression, but not that induced by microtubule depolymerization. The combination of Mad2 overexpression and TRIP13 loss reduced the ability of checkpoint complexes to disassemble and significantly inhibited the proliferation of cells in culture and tumor xenografts. These results identify an unexpected dependency on TRIP13 in cells overexpressing Mad2.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mad2; TRIP13; cancer; cell cycle; mitosis; mitotic checkpoint; spindle assembly checkpoint

Mesh:

Substances:

Year:  2017        PMID: 28564602      PMCID: PMC5526606          DOI: 10.1016/j.celrep.2017.05.021

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  49 in total

1.  Role of CCT chaperonin in the disassembly of mitotic checkpoint complexes.

Authors:  Sharon Kaisari; Danielle Sitry-Shevah; Shirly Miniowitz-Shemtov; Adar Teichner; Avram Hershko
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

2.  Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition.

Authors:  Juan-Manuel Schvartzman; Pascal H G Duijf; Rocio Sotillo; Courtney Coker; Robert Benezra
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

3.  Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.

Authors:  Rocío Sotillo; Eva Hernando; Elena Díaz-Rodríguez; Julie Teruya-Feldstein; Carlos Cordón-Cardo; Scott W Lowe; Robert Benezra
Journal:  Cancer Cell       Date:  2006-12-28       Impact factor: 31.743

4.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

5.  c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.

Authors:  Antje Menssen; Alexey Epanchintsev; Dmitri Lodygin; Nousin Rezaei; Peter Jung; Berlinda Verdoodt; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-02-03       Impact factor: 4.534

6.  Nuclear pores protect genome integrity by assembling a premitotic and Mad1-dependent anaphase inhibitor.

Authors:  Veronica Rodriguez-Bravo; John Maciejowski; Jennifer Corona; Håkon Kirkeby Buch; Philippe Collin; Masato T Kanemaki; Jagesh V Shah; Prasad V Jallepalli
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

7.  Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex.

Authors:  Laura Hewitt; Anthony Tighe; Stefano Santaguida; Anne M White; Clifford D Jones; Andrea Musacchio; Stephen Green; Stephen S Taylor
Journal:  J Cell Biol       Date:  2010-07-12       Impact factor: 10.539

8.  Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors.

Authors:  Yang Bian; Risa Kitagawa; Parmil K Bansal; Yo Fujii; Alexander Stepanov; Katsumi Kitagawa
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-14       Impact factor: 11.205

9.  Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2.

Authors:  V Sudakin; G K Chan; T J Yen
Journal:  J Cell Biol       Date:  2001-09-03       Impact factor: 10.539

10.  TRIP13PCH-2 promotes Mad2 localization to unattached kinetochores in the spindle checkpoint response.

Authors:  Christian R Nelson; Tom Hwang; Pin-Hsi Chen; Needhi Bhalla
Journal:  J Cell Biol       Date:  2015-11-02       Impact factor: 10.539

View more
  18 in total

1.  Design, Synthesis, and Biological Evaluation of Apcin-Based CDC20 Inhibitors.

Authors:  Rajib Bhuniya; Xinrui Yuan; Longchuan Bai; Kathryn L Howie; Rui Wang; Wei Li; Frank Park; Chao-Yie Yang
Journal:  ACS Med Chem Lett       Date:  2022-01-18       Impact factor: 4.345

2.  TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.

Authors:  Zhi-Han Li; Lei Lei; Liang-Ru Fei; Wen-Jing Huang; Yi-Wen Zheng; Mai-Qing Yang; Zhao Wang; Chen-Chen Liu; Hong-Tao Xu
Journal:  J Mol Histol       Date:  2020-10-30       Impact factor: 2.611

3.  Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.

Authors:  K L Thu; J Silvester; M J Elliott; W Ba-Alawi; M H Duncan; A C Elia; A S Mer; P Smirnov; Z Safikhani; B Haibe-Kains; T W Mak; D W Cescon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

4.  A chemical genetics approach to examine the functions of AAA proteins.

Authors:  Tommaso Cupido; Natalie H Jones; Michael J Grasso; Rudolf Pisa; Tarun M Kapoor
Journal:  Nat Struct Mol Biol       Date:  2021-03-29       Impact factor: 15.369

5.  Mechanistic insight into TRIP13-catalyzed Mad2 structural transition and spindle checkpoint silencing.

Authors:  Melissa L Brulotte; Byung-Cheon Jeong; Faxiang Li; Bing Li; Eric B Yu; Qiong Wu; Chad A Brautigam; Hongtao Yu; Xuelian Luo
Journal:  Nat Commun       Date:  2017-12-05       Impact factor: 14.919

Review 6.  APC/C: current understanding and future perspectives.

Authors:  Hiroyuki Yamano
Journal:  F1000Res       Date:  2019-05-23

7.  Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.

Authors:  Yanjun Gao; Shanhui Liu; Qi Guo; Su Zhang; Youli Zhao; Hanzhang Wang; Tianbao Li; Yuwen Gong; Yuhan Wang; Tao Zhang; Zhilong Dong; Dean Bacich; Wasim H Chowdhury; Ronald Rodriguez; Zhiping Wang
Journal:  Int J Biol Sci       Date:  2019-06-02       Impact factor: 6.580

8.  TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.

Authors:  Nengquan Sheng; Li Yan; Kai Wu; Weiqiang You; Jianfeng Gong; Landian Hu; Gewen Tan; Hongqi Chen; Zhigang Wang
Journal:  Cell Death Dis       Date:  2018-03-14       Impact factor: 8.469

9.  TRIP13 and APC15 drive mitotic exit by turnover of interphase- and unattached kinetochore-produced MCC.

Authors:  Dong Hyun Kim; Joo Seok Han; Peter Ly; Qiaozhen Ye; Moira A McMahon; Kyungjae Myung; Kevin D Corbett; Don W Cleveland
Journal:  Nat Commun       Date:  2018-10-19       Impact factor: 14.919

Review 10.  Applications of Genome Editing Technology in Research on Chromosome Aneuploidy Disorders.

Authors:  Silvia Natsuko Akutsu; Kazumasa Fujita; Keita Tomioka; Tatsuo Miyamoto; Shinya Matsuura
Journal:  Cells       Date:  2020-01-17       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.